Show simple item record

dc.contributor.authorWu, Ann Chen
dc.contributor.authorGay, Charlene
dc.contributor.authorRett, Melisa
dc.contributor.authorStout, Natasha Kay
dc.contributor.authorWeiss, Scott Tillman
dc.contributor.authorFuhlbrigge, Anne Louise
dc.date.accessioned2016-05-17T19:48:21Z
dc.date.issued2015
dc.identifier.citationWu, Ann Chen, Charlene Gay, Melisa D Rett, Natasha Stout, Scott T Weiss, and Anne L Fuhlbrigge. 2015. “Pharmacogenomic Test That Predicts Response to Inhaled Corticosteroids in Adults with Asthma Likely to Be Cost-Saving.” Pharmacogenomics 16 (6) (April): 591–600. doi:10.2217/pgs.15.28.en_US
dc.identifier.issn1462-2416en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27015682
dc.description.abstractAim: To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to inhaled corticosteroids might be a cost-effective option for individuals with asthma. Materials & methods: We synthesized published data on clinical and economic outcomes to project 10-year costs, quality-adjusted life-years and cost–effectiveness of pharmacogenomic testing for inhaled corticosteroid response. We assumed the pharmacogenomic test cost was $500 with a sensitivity and specificity of 84 and 98%, respectively. These were varied in sensitivity analyses. Results: Both strategies, pharmacogenomic testing for inhaled corticosteroid response and no testing conferred 7.1 quality-adjusted life-years. Compared with no testing, pharmacogenomic testing costs less. Conclusion: Pharmacogenomic testing for asthma is cost-saving and noninferior in improving health.en_US
dc.language.isoen_USen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.isversionofdoi:10.2217/pgs.15.28en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545673/en_US
dash.licenseOAP
dc.subjectasthmaen_US
dc.subjectcost–effectivenessen_US
dc.subjectinhaled corticosteroidsen_US
dc.subjectpharmacogenomicsen_US
dc.subjectpredictive testen_US
dc.titlePharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-savingen_US
dc.typeJournal Articleen_US
dc.description.versionAccepted Manuscripten_US
dc.relation.journalPharmacogenomicsen_US
dash.depositing.authorWeiss, Scott Tillman
dc.date.available2016-05-17T19:48:21Z
dc.identifier.doi10.2217/pgs.15.28*
dash.contributor.affiliatedStout, Natasha
dash.contributor.affiliatedFuhlbrigge, Anne
dash.contributor.affiliatedRett, Melisa D.
dash.contributor.affiliatedWu, Ann
dash.contributor.affiliatedWeiss, Scott


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record